Rapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung Cancer

Clinical trial NCT02770014 · TERMINATED

Trial details

NCT number: NCT02770014
Sponsor: Dana-Farber Cancer Institute
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer

Start date: 2016-06-01
Primary completion: 2019-04-16
Enrollment: 43

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.